Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial

Jens-Ulrik S Jensen, Theis S Itenov, Katrin M Thormar, Lars Hein, Thomas T Mohr, Mads H Andersen, Jesper Løken, Hamid Tousi, Bettina Lundgren, Hans Christian Boesen, Maria E Johansen, Sisse R Ostrowski, Pär I Johansson, Jesper Grarup, Jørgen Vestbo, Jens D Lundgren, Procalcitonin And Survival Study (PASS) Group, M Steensen, K Thornberg, M Bestle, D Strange, A Ø Lauritsen, P Søe-Jensen, N Reiter, N E Drenck, P Fjeldborg, Z Fox, J Kjær, D Kristensen, M B Rasmussen, C S V Hallas, M Zacho, C Østergaard, P L Petersen, S Hougaard, T Mantoni, L Nebrich, A Bendtsen, L H Andersen, F Bærentzen, Andreas Eversbusch, B Bømler, R Martusevicius, T Nielsen, P M Bådstøløkken, U Grevstad, P Hallas, A Lindhardt, T Galle, K Graeser, E Hohwu-Christensen, P Gregersen, L M Pedersen, I Rye, J Cordtz, K R Madsen, P R C Kirkegaard, L Findsen, L H Nielsen, D H Pedersen, J H Andersen, C Albrechtsen, A Jacobsen, T Jansen, A G Jensen, H H Jørgensen, M Vazin, L Lipsius, M Skielboe, B Thage, C Thoft, M Uldbjerg, E Anderlo, M Engsig, F Hani, R B Jacobsen, L Mulla, U Skram, T Waldau, T Faber, B Andersen, I Gillesberg, A Christensen, C Hartmann, R Albret, D S Dinesen, K Gani, M Ibsen, J A Petersen, P Carl, E Gade, D Solevad, C Heiring, M Jørgensen, K Ekelund, A Afshari, N Hammer, M Bitsch, J S Hansen, C Wamberg, T D Clausen, R Winkel, J Huusom, D L Buck, U Grevstad, K Lenz, P Mellado, H Karacan, J Hidestål, J Høgagard, J Højbjerg, J Højlund, S Hestad, M Østergaard, N Wesche, S A Nielsen, H Christensen, H Blom, C H Jensen, K Nielsen, N G Holler, C D Rossau, M Glæemose, M B Wranér, C B Thomsen, B Rasmussen, C Lund-Rasmussen, B Bech, K Bjerregaard, L Spliid, L L W Nielsen, K M Larsen, M Goldinger, D Illum, C Jessen, A Christiansen, A Berg, T Elkmann, J A K Pedersen, M Simonsen, H Joensen, H Alstrøm, C Svane, A Engquist, Jens-Ulrik S Jensen, Theis S Itenov, Katrin M Thormar, Lars Hein, Thomas T Mohr, Mads H Andersen, Jesper Løken, Hamid Tousi, Bettina Lundgren, Hans Christian Boesen, Maria E Johansen, Sisse R Ostrowski, Pär I Johansson, Jesper Grarup, Jørgen Vestbo, Jens D Lundgren, Procalcitonin And Survival Study (PASS) Group, M Steensen, K Thornberg, M Bestle, D Strange, A Ø Lauritsen, P Søe-Jensen, N Reiter, N E Drenck, P Fjeldborg, Z Fox, J Kjær, D Kristensen, M B Rasmussen, C S V Hallas, M Zacho, C Østergaard, P L Petersen, S Hougaard, T Mantoni, L Nebrich, A Bendtsen, L H Andersen, F Bærentzen, Andreas Eversbusch, B Bømler, R Martusevicius, T Nielsen, P M Bådstøløkken, U Grevstad, P Hallas, A Lindhardt, T Galle, K Graeser, E Hohwu-Christensen, P Gregersen, L M Pedersen, I Rye, J Cordtz, K R Madsen, P R C Kirkegaard, L Findsen, L H Nielsen, D H Pedersen, J H Andersen, C Albrechtsen, A Jacobsen, T Jansen, A G Jensen, H H Jørgensen, M Vazin, L Lipsius, M Skielboe, B Thage, C Thoft, M Uldbjerg, E Anderlo, M Engsig, F Hani, R B Jacobsen, L Mulla, U Skram, T Waldau, T Faber, B Andersen, I Gillesberg, A Christensen, C Hartmann, R Albret, D S Dinesen, K Gani, M Ibsen, J A Petersen, P Carl, E Gade, D Solevad, C Heiring, M Jørgensen, K Ekelund, A Afshari, N Hammer, M Bitsch, J S Hansen, C Wamberg, T D Clausen, R Winkel, J Huusom, D L Buck, U Grevstad, K Lenz, P Mellado, H Karacan, J Hidestål, J Høgagard, J Højbjerg, J Højlund, S Hestad, M Østergaard, N Wesche, S A Nielsen, H Christensen, H Blom, C H Jensen, K Nielsen, N G Holler, C D Rossau, M Glæemose, M B Wranér, C B Thomsen, B Rasmussen, C Lund-Rasmussen, B Bech, K Bjerregaard, L Spliid, L L W Nielsen, K M Larsen, M Goldinger, D Illum, C Jessen, A Christiansen, A Berg, T Elkmann, J A K Pedersen, M Simonsen, H Joensen, H Alstrøm, C Svane, A Engquist

Abstract

Background: It is unclear whether biomarkers of alveolar damage (surfactant protein D, SPD) or conductive airway damage (club cell secretory protein 16, CC16) measured early after intensive care admittance are associated with one-month clinical respiratory prognosis. If patients who do not recover respiratory function within one month can be identified early, future experimental lung interventions can be aimed toward this high-risk group. We aimed to determine, in a heterogenous critically ill population, whether baseline profound alveolar damage or conductive airway damage has clinical respiratory impact one month after intensive care admittance.

Methods: Biobank study of biomarkers of alveolar and conductive airway damage in intensive care patients was conducted. This was a sub-study of 758 intubated patients from a 1200-patient randomized trial. We split the cohort into a "learning cohort" and "validating cohort" based on geographical criteria: northern sites (learning) and southern sites (validating).

Results: Baseline SPD above the 85th percentile in the "learning cohort" predicted low chance of successful weaning from ventilator within 28 days (adjusted hazard ratio 0.6 [95% CI 0.4-0.9], p = 0.005); this was confirmed in the validating cohort. CC16 did not predict the endpoint. The absolute risk of not being successfully weaned within the first month was 48/106 (45.3%) vs. 175/652 (26.8%), p < 0.0001 (high SPD vs. low SPD). The chance of being "alive and without ventilator ≥20 days within the first month" was lower among patients with high SPD (adjusted OR 0.2 [95% CI 0.2-0.4], p < 0.0001), confirmed in the validating cohort, and the risk of ARDS was higher among patients with high SPD (adjusted OR 3.4 [95% CI 1.0-11.4], p = 0.04)-also confirmed in the validating cohort.

Conclusion: Early profound alveolar damage in intubated patients can be identified by SPD blood measurement at intensive care admission, and high SPD level is a strong independent predictor that the patient suffers from ARDS and will not recover independent respiratory function within one month. This knowledge can be used to improve diagnostic and prognostic models and to identify the patients who most likely will benefit from experimental interventions aiming to preserve alveolar tissue and therefore respiratory function. Trial registration This is a sub-study to the Procalcitonin And Survival Study (PASS), Clinicaltrials.gov ID: NCT00271752, first registered January 1, 2006.

Keywords: Biomarkers; Lung damage; Mechanical ventilation; Personalized early intervention.

Figures

Fig. 1
Fig. 1
Flowchart of patients in the study. PASS: the Procalcitonin And Survival Study, a 1200-patient intensive care randomized trial [21]
Fig. 2
Fig. 2
Surfactant protein D serum levels according to primary admission reason. a “Learning cohort”/northern sites. b “Validating cohort.” Boxes are medians and interquartile ranges. Whiskers are total range. Rhombuses are means
Fig. 3
Fig. 3
Cumulative incidence of successful weaning from respirator within 28 days after intensive care admission and death while intubated—total cohort (“learning”/northern cohort + “validating”/southern cohort). The two upper curves are regarding “successful weaning from respirator” (vs. still intubated at day 28); the two lower curves are regarding “dead while intubated” (vs. alive at day 28). Patients extubated <48 h at death were counted as “dead while intubated.” Patients extubated and alive at day 28 and those extubated ≥48 h at death were counted as successfully weaned from ventilator. N = 758. Gray scales are 95% CI. SPD surfactant protein D. “High SPD is >525.6 ng/mL
Fig. 4
Fig. 4
Adjusted odds ratios for the patient being “alive and without mechanical ventilation for ≥20 days within first 28 days after ICU admission.” All variables were entered in the same logistic regression model. The graph is separated to display odds ratios for both binary and continuous covariates. Cut points for SP-D and CC16 are equal to upper 15 percentile in the northern/learning cohort. Boxes and whiskers are odds ratio and 95% CIs, respectively

References

    1. Sellares J, Ferrer M, Cano E, Loureiro H, Valencia M, Torres A. Predictors of prolonged weaning and survival during ventilator weaning in a respiratory ICU. Intensive Care Med. 2011;37:775–784. doi: 10.1007/s00134-011-2179-3.
    1. Eisner MD, Parsons P, Matthay MA, Ware L, Greene K. Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax. 2003;58:983–988. doi: 10.1136/thorax.58.11.983.
    1. Determann RM, Millo JL, Waddy S, Lutter R, Garrard CS, Schultz MJ. Plasma CC16 levels are associated with development of ALI/ARDS in patients with ventilator-associated pneumonia: a retrospective observational study. BMC Pulm Med. 2009;9:49. doi: 10.1186/1471-2466-9-49.
    1. Calfee CS, Ware LB, Glidden DV, Eisner MD, Parsons PE, Thompson BT, Matthay MA. Use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injury. Crit Care Med. 2011;39:711–717. doi: 10.1097/CCM.0b013e318207ec3c.
    1. Todd DA, Marsh MJ, George A, Henderson NG, Barr H, Sebastian S, Clark GT, Koster G, Clark HW, Postle AD. Surfactant phospholipids, surfactant proteins, and inflammatory markers during acute lung injury in children. Pediatr Crit Care Med. 2010;11:82–91. doi: 10.1097/PCC.0b013e3181ae5a4c.
    1. Ferguson ND, Fan E, Camporota L, Antonelli M, Anzueto A, Beale R, Brochard L, Brower R, Esteban A, Gattinoni L, Rhodes A, Slutsky AS, Vincent JL, Rubenfeld GD, Thompson BT, Ranieri VM. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med. 2012;38:1573–1582. doi: 10.1007/s00134-012-2682-1.
    1. Crouch E, Wright JR. Surfactant proteins a and d and pulmonary host defense. Annu Rev Physiol. 2001;63:521–554. doi: 10.1146/annurev.physiol.63.1.521.
    1. Crouch EC, Persson A, Griffin GL, Chang D, Senior RM. Interactions of pulmonary surfactant protein D (SP-D) with human blood leukocytes. Am J Respir Cell Mol Biol. 1995;12:410–415. doi: 10.1165/ajrcmb.12.4.7695920.
    1. Borron PJ, Crouch EC, Lewis JF, Wright JR, Possmayer F, Fraher LJ. Recombinant rat surfactant-associated protein D inhibits human T lymphocyte proliferation and IL-2 production. J Immunol. 1998;161:4599–4603.
    1. Madan T, Eggleton P, Kishore U, Strong P, Aggrawal SS, Sarma PU, Reid KB. Binding of pulmonary surfactant proteins A and D to Aspergillus fumigatus conidia enhances phagocytosis and killing by human neutrophils and alveolar macrophages. Infect Immun. 1997;65:3171–3179.
    1. Jain D, Atochina-Vasserman EN, Tomer Y, Kadire H, Beers MF. Surfactant protein D protects against acute hyperoxic lung injury. Am J Respir Crit Care Med. 2008;178:805–813. doi: 10.1164/rccm.200804-582OC.
    1. Cutz E, Conen PE. Ultrastructure and cytochemistry of Clara cells. Am J Pathol. 1971;62:127–141.
    1. Bernard A, Dumont X, Roels H, Lauwerys R, Dierynck I, De Ley M, Stroobant V, de Hoffmann E. The molecular mass and concentrations of protein 1 or Clara cell protein in biological fluids: a reappraisal. Clin Chim Acta. 1993;223:189–191. doi: 10.1016/0009-8981(93)90077-H.
    1. Johansson S, Wennergren G, Aberg N, Rudin A. Clara cell 16-kd protein downregulates T(H)2 differentiation of human naive neonatal T cells. J Allergy Clin Immunol. 2007;120:308–314. doi: 10.1016/j.jaci.2007.03.021.
    1. Bernard A, Roels H, Buchet JP, Lauwerys R. Decrease of serum Clara cell protein in smokers. Lancet. 1992;339:1620. doi: 10.1016/0140-6736(92)91891-B.
    1. Arsalane K, Broeckaert F, Knoops B, Wiedig M, Toubeau G, Bernard A. Clara cell specific protein (CC16) expression after acute lung inflammation induced by intratracheal lipopolysaccharide administration. Am J Respir Crit Care Med. 2000;161:1624–1630. doi: 10.1164/ajrccm.161.5.9812157.
    1. Kropski JA, Fremont RD, Calfee CS, Ware LB. Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury. Chest. 2009;135:1440–1447. doi: 10.1378/chest.08-2465.
    1. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Loken J, Steensen M, Fox Z, Tousi H, Soe-Jensen P, Lauritsen AO, Strange D, Petersen PL, Reiter N, Hestad S, Thormar K, Fjeldborg P, Larsen KM, Drenck NE, Ostergaard C, Kjaer J, Grarup J, Lundgren JD, Procalcitonin, Survival Study G Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med. 2011;39:2048–2058. doi: 10.1097/CCM.0b013e31821e8791.
    1. Agency EM. Note for Guidance on Good Clinical Practice, EMEA (European Medicines Agency) [Consensus document]. July 2002. . Accessed Jan 5, 2014.
    1. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Loken J, Steensen M, Fox Z, Tousi H, Soe-Jensen P, Lauritsen AO, Strange D, Petersen PL, Reiter N, Hestad S, Thormar K, Fjeldborg P, Larsen KM, Drenck NE, Ostergaard C, Kjaer J, Grarup J, Lundgren JD. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med. 2011;39(9):2048–2058. doi: 10.1097/CCM.0b013e31821e8791.
    1. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr T, Andersen MH, Thornberg KJ, Loken J, Steensen M, Fox Z, Tousi H, Soe-Jensen P, Lauritsen AO, Strange DG, Reiter N, Thormar K, Fjeldborg PC, Larsen KM, Drenck NE, Johansen ME, Nielsen LR, Ostergaard C, Kjaer J, Grarup J, Lundgren JD, Procalcitonin, Survival Study G Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial. BMJ Open. 2012;2:e000635. doi: 10.1136/bmjopen-2011-000635.
    1. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, Ranieri M, Rubenfeld G, Thompson BT, Wrigge H, Slutsky AS, Pesenti A, Investigators LS, Group ET Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315:788–800. doi: 10.1001/jama.2016.0291.
    1. Kor DJ, Lingineni RK, Gajic O, Park PK, Blum JM, Hou PC, Hoth JJ, Anderson HL, 3rd, Bajwa EK, Bartz RR, Adesanya A, Festic E, Gong MN, Carter RE, Talmor DS. Predicting risk of postoperative lung injury in high-risk surgical patients: a multicenter cohort study. Anesthesiology. 2014;120:1168–1181. doi: 10.1097/ALN.0000000000000216.
    1. Gaunsbaek MQ, Rasmussen KJ, Beers MF, Atochina-Vasserman EN, Hansen S. Lung surfactant protein D (SP-D) response and regulation during acute and chronic lung injury. Lung. 2013;191:295–303. doi: 10.1007/s00408-013-9452-x.
    1. Guzel A, Karadag A, Okuyucu A, Alacam H, Kucuk Y. The evaluation of serum surfactant protein D (SP-D) levels as a biomarker of lung injury in tuberculosis and different lung diseases. Clin Lab. 2014;60:1091–1098.
    1. Bertozzi P, Astedt B, Zenzius L, Lynch K, LeMaire F, Zapol W, Chapman HA., Jr Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med. 1990;322:890–897. doi: 10.1056/NEJM199003293221304.
    1. Guerin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, Mercier E, Badet M, Mercat A, Baudin O, Clavel M, Chatellier D, Jaber S, Rosselli S, Mancebo J, Sirodot M, Hilbert G, Bengler C, Richecoeur J, Gainnier M, Bayle F, Bourdin G, Leray V, Girard R, Baboi L, Ayzac L. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368:2159–2168. doi: 10.1056/NEJMoa1214103.
    1. Zhu B, Li Z, Jiang L, Du B, Jiang Q, Wang M, Lou R, Xi X. Effect of a quality improvement program on weaning from mechanical ventilation: a cluster randomized trial. Intensive Care Med. 2015;41:1781–1790. doi: 10.1007/s00134-015-3958-z.
    1. Uchida T, Shirasawa M, Ware LB, Kojima K, Hata Y, Makita K, Mednick G, Matthay ZA, Matthay MA. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med. 2006;173:1008–1015. doi: 10.1164/rccm.200509-1477OC.
    1. Calfee CS, Ware LB, Eisner MD, Parsons PE, Thompson BT, Wickersham N, Matthay MA, Network NA. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax. 2008;63:1083–1089. doi: 10.1136/thx.2008.095588.
    1. Jabaudon M, Blondonnet R, Roszyk L, Bouvier D, Audard J, Clairefond G, Fournier M, Marceau G, Dechelotte P, Pereira B, Sapin V, Constantin JM. Soluble receptor for advanced glycation end-products predicts impaired alveolar fluid clearance in acute respiratory distress syndrome. Am J Respir Crit Care Med. 2015;192:191–199. doi: 10.1164/rccm.201501-0020OC.

Source: PubMed

3
Abonnieren